Dr. Percival is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-598-6190
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2007 - 2010
Stanford University School of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2009 - Present
WA State Medical License 2015 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Start of enrollment: 2016 Sep 22
- Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia Start of enrollment: 2018 Nov 30
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms Start of enrollment: 2023 Dec 18
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 172 citationsAcute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN GuidelinesDaniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Vijaya Raj Bhatt, Jessica K. Altman
Journal of the National Comprehensive Cancer Network. 2021-01-06 - 10 citationsEarly hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.Anna B. Halpern, Nicholas P Howard, Megan Othus, Paul C. Hendrie, Nikita V Baclig
Leukemia. 2020-02-01 - 3 citationsComparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy.Anna B. Halpern, Megan Othus, Nicholas P Howard, Paul C. Hendrie, Mary-Elizabeth M. Percival
Leukemia & Lymphoma. 2021-10-05
Abstracts/Posters
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Mary-Elizabeth M. Percival, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast CountMary-Elizabeth M. Percival, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe...Mary-Elizabeth M. Percival, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Clinical Challenge: Hematologic Malignancy and COVID-19June 17th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
